Cargando…
MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities
Ovarian cancer comprises one of the three major malignant tumor types in the female reproductive system. The mortality rate of this cancer is the highest among all gynecological tumors, with ovarian cancer metastasis constituting an important cause of death. Therefore, markers for disease prediction...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539609/ https://www.ncbi.nlm.nih.gov/pubmed/31035447 http://dx.doi.org/10.3390/ijerph16091510 |
_version_ | 1783422430403887104 |
---|---|
author | Chen, San-Nung Chang, Renin Lin, Li-Te Chern, Chyi-Uei Tsai, Hsiao-Wen Wen, Zhi-Hong Li, Yi-Han Li, Chia-Jung Tsui, Kuan-Hao |
author_facet | Chen, San-Nung Chang, Renin Lin, Li-Te Chern, Chyi-Uei Tsai, Hsiao-Wen Wen, Zhi-Hong Li, Yi-Han Li, Chia-Jung Tsui, Kuan-Hao |
author_sort | Chen, San-Nung |
collection | PubMed |
description | Ovarian cancer comprises one of the three major malignant tumor types in the female reproductive system. The mortality rate of this cancer is the highest among all gynecological tumors, with ovarian cancer metastasis constituting an important cause of death. Therefore, markers for disease prediction and prognosis are highly desirable for early diagnosis as well as for helping optimize and personalize treatment. Recently, microRNAs (miRNAs), which consist of short-sequence RNAs that do not encode a protein, have emerged as new biomarkers in the clinical diagnosis and treatment of ovarian cancer. By pairing with bases specific to the target messenger RNA (mRNA), miRNAs cause degradation of the target mRNA or inhibit its translation, thereby regulating various cellular processes including cell proliferation and adhesion. Increasing numbers of studies have shown that miRNA expression abnormality plays an important role in the development of ovarian cancer. In this review, we discuss the mechanisms of miRNA action, current research regarding their role in the suppression or promotion of ovarian cancer, and their use as markers for diagnosis of prognosis or as therapeutic targets for this disease. Finally, we present future perspectives regarding the clinical management of ovarian cancer and the role for miRNAs therein. |
format | Online Article Text |
id | pubmed-6539609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65396092019-06-05 MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities Chen, San-Nung Chang, Renin Lin, Li-Te Chern, Chyi-Uei Tsai, Hsiao-Wen Wen, Zhi-Hong Li, Yi-Han Li, Chia-Jung Tsui, Kuan-Hao Int J Environ Res Public Health Review Ovarian cancer comprises one of the three major malignant tumor types in the female reproductive system. The mortality rate of this cancer is the highest among all gynecological tumors, with ovarian cancer metastasis constituting an important cause of death. Therefore, markers for disease prediction and prognosis are highly desirable for early diagnosis as well as for helping optimize and personalize treatment. Recently, microRNAs (miRNAs), which consist of short-sequence RNAs that do not encode a protein, have emerged as new biomarkers in the clinical diagnosis and treatment of ovarian cancer. By pairing with bases specific to the target messenger RNA (mRNA), miRNAs cause degradation of the target mRNA or inhibit its translation, thereby regulating various cellular processes including cell proliferation and adhesion. Increasing numbers of studies have shown that miRNA expression abnormality plays an important role in the development of ovarian cancer. In this review, we discuss the mechanisms of miRNA action, current research regarding their role in the suppression or promotion of ovarian cancer, and their use as markers for diagnosis of prognosis or as therapeutic targets for this disease. Finally, we present future perspectives regarding the clinical management of ovarian cancer and the role for miRNAs therein. MDPI 2019-04-29 2019-05 /pmc/articles/PMC6539609/ /pubmed/31035447 http://dx.doi.org/10.3390/ijerph16091510 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chen, San-Nung Chang, Renin Lin, Li-Te Chern, Chyi-Uei Tsai, Hsiao-Wen Wen, Zhi-Hong Li, Yi-Han Li, Chia-Jung Tsui, Kuan-Hao MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities |
title | MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities |
title_full | MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities |
title_fullStr | MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities |
title_full_unstemmed | MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities |
title_short | MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities |
title_sort | microrna in ovarian cancer: biology, pathogenesis, and therapeutic opportunities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539609/ https://www.ncbi.nlm.nih.gov/pubmed/31035447 http://dx.doi.org/10.3390/ijerph16091510 |
work_keys_str_mv | AT chensannung micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT changrenin micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT linlite micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT chernchyiuei micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT tsaihsiaowen micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT wenzhihong micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT liyihan micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT lichiajung micrornainovariancancerbiologypathogenesisandtherapeuticopportunities AT tsuikuanhao micrornainovariancancerbiologypathogenesisandtherapeuticopportunities |